Últimas noticias sobre Global X Cybersecurity ETF (NASDAQ:BUG)

Technology

Other

The Fund invests at least 80 percent of its total assets in the securities of the Indxx Cybersecurity Index (Underlying Index) and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund will also invest, under normal circumstances, at least 80 percent of its net assets, plus borrowings for investment purposes (if any), in Cybersecurity Companies (as defined below), and in ADRs and GDRs based on such securities. The Fund's 80 percent investment policies are non-fundamental and require 60 days prior written notice to shareholders before they can be changed. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received).

Check Point Software Technologies Ltd.

Palo Alto Networks Inc.

Zscaler Inc

Gen Digital Inc

Okta Inc.

Varonis Systems Inc

Fortinet Inc.

SentinelOne Inc.

Global X Cybersecurity ETF

Sector ETFs

Politics

Global

Tech

ETFs

$FTT

CHKP

CIBR

CRWD

CSCO

HACK

PANW

Los ETF de ciberseguridad son una opción atractiva de inversión mientras las amenazas digitales aumentan. Descubre los principales ETFs

Ciberseguridad: ETF clave para invertir ante la creciente amenaza global

BUMRUNGRAD HOSPITAL NVDR by Bumrungrad Hospital Public Co., Ltd.

Bumrungrad Hospital PCL

Bluglass Ltd

PRIMO NUTRACEUTICALS by Primo Nutraceuticals Inc.

JP Morgan analyst Matthew Boss maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Neutral and lowers the price target from $43 to $35.

News

Price Target

Analyst Ratings

VSCO

JP Morgan Maintains Neutral on Victoria's Secret, Lowers Price Target to $35

Macy&#8217;s&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower in premarket</a> on Thursday after the fourth-quarter earnings.
The company reported a fourth-quarter sales decline of 4.3% year-on-year to $7.768 billion, missing the <a href="https://www.benzinga.com/pressreleases/25/03/b44161902/macys-inc-reports-fourth-quarter-and-fiscal-year-2024-results" target="_blank" rel="noreferrer noopener">analyst consensus of $7.867 billion.</a>
Comparable sales decreased 1.1% on an owned basis and up&nbsp;0.2%&nbsp;on an owned-plus-licensed-plus-marketplace basis.
The company&#8217;s go-forward business&nbsp;comparable sales were down&nbsp;0.7%&nbsp;on an owned basis and up&nbsp;0.6%&nbsp;on an owned-plus-licensed-plus-marketplace basis.&nbsp;
By nameplate, Macy&#8217;s net sales were down&nbsp;5.3%, with comparable sales down&nbsp;1.9%&nbsp;on an owned basis and down&nbsp;0.9%&nbsp;on an owned-plus-licensed-plus-marketplace basis.
Bloomingdale&#8217;s net sales were up 2.0%, with comparable sales up 4.8% on an owned basis and up 6.5% on an owned-plus-licensed-plus-marketplace basis. Bluemercury net sales rose 2.4%, and comparable sales grew 6.2% on an owned basis.
The operating margin was 6.2%. Operating income for the quarter was $500 million compared to a loss of $149 million last year.
The gross margin was 35.7%, down 80 basis points from the prior year. Adjusted EBITDA was $903 million versus $1.09 billion last year. Adjusted EPS of $1.80 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus estimate of $1.53.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44147956/ross-stores-faces-slower-growth-with-shifts-in-lower-income-customers-preference-says-analyst" rel="noreferrer noopener">Ross Stores Faces Slower Growth With Shifts In Lower-Income Customers Preference, Says Analyst</a>
Macy&#8217;s&nbsp;held $1.3 billion in cash and equivalents&nbsp;as of February 1.&nbsp;Operating cash flow for twelve months totaled $1.3 billion with a free cash flow of $679 million.
Merchandise inventories were up 2.5%&nbsp;year-over-year. As of the end of FY24, total debt was $2.8 billion.
&#8220;As we close out the first year of the Bold New Chapter strategy, investments in the customer experience enabled us to achieve our highest comparable sales of the year, our best performance in 11 quarters,&#8221; said&nbsp;chairman&nbsp;and CEO Tony Spring.
Outlook: Macy&#8217;s expects FY25 revenue of $21.0 billion – $21.4 billion, against the consensus of $21.811 billion. The company sees FY25 adjusted EPS of $2.05 &#8211; $2.25 against the estimate of $2.31.
Macy&#8217;s&nbsp;currently sees FY25 comparable owned-plus-licensed-plus-marketplace sales <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">of -2% to -0.5%.</a>
Price Action: M shares traded lower by 4.13% at $12.76 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44143576/apples-latest-macbook-air-with-m4-chip-is-twice-as-fast-as-its-predecessor-with-lower-price" target="_blank" rel="noreferrer noopener">Apple&#8217;s Latest MacBook Air With M4 Chip Is Twice As Fast As Its Predecessor With Lower Price</a></li>
</ul>
Photo via Shutterstock.

Equities

Movers

General

Macy's Q4 Revenue Lag And Annual Outlook Disappoints Investors, Stock Slides

JP Morgan analyst Ken Goldman maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Neutral and lowers the price target from $29 to $26.

JP Morgan Maintains Neutral on Conagra Brands, Lowers Price Target to $26

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) sees FY2025 sales of $420.000 million-$450.000 million vs $450.04 million analyst estimate.

Guidance

HIPO

Hippo Holdings Sees FY2025 Sales $420.000M-$450.000M vs $450.04M Est

Contracts

Jacobs Awarded Operational Technology Cybersecurity Contract, Valued At $13.4M, With Hampton Roads Sanitation District

Benchmark analyst Cody Acree reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $135 price target.

Reiteration

MRVL

Benchmark Reiterates Buy on Marvell Tech, Maintains $135 Price Target

JP Morgan analyst Karen Li upgrades Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) from Neutral to Overweight and raises the price target from $13 to $18.

Upgrades

JP Morgan Upgrades Full Truck Alliance Co to Overweight, Raises Price Target to $18

Needham analyst Mike Cikos maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $415 to $270.

Needham Maintains Buy on MongoDB, Lowers Price Target to $270

Needham analyst Ryan MacDonald reiterates LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) from Hold to Hold.

LPSN

Needham Reiterates Hold on LivePersonto Hold

Needham analyst Ryan MacDonald reiterates Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) with a Buy and maintains $10 price target.

YEXT

Needham Reiterates Buy on Yext, Maintains $10 Price Target

Needham analyst Ryan MacDonald reiterates Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and maintains $270 price target.

VEEV

Needham Reiterates Buy on Veeva Systems, Maintains $270 Price Target

JP Morgan analyst Brian Essex maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Overweight and raises the price target from $240 to $250.

JP Morgan Maintains Overweight on Zscaler, Raises Price Target to $250

WIIM

SCNX

Scienture shares are trading higher after the company partnered with Kindeva to launch the 10mg REZENOPY nasal spray for opioid overdose treatment.

Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.32 by 6.25 percent. The company reported quarterly sales of $3.44 million which missed the analyst consensus estimate of $3.53 million by 2.33 percent.

Earnings

Earnings Misses

SUNS

Sunrise Realty Trust Q4 Adj EPS $0.30 Misses $0.32 Estimate, Sales $3.44M Miss $3.53M Estimate

PSTV

Plus Therapeutics shares are trading higher after the company was granted FDA orphan drug designation for Rhenium Obisbemeda in leptomeningeal metastases in patients with lung cancer.

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY&#xAE; (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY&#xAE; (naloxone HCl) Nasal Spray 10mg. Scienture will own the new drug application (NDA) for REZENOPY&#xAE; in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.
REZENOPY&#xAE; is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids.
The addition of REZENOPY&#xAE; to Scienture's product portfolio aligns with Scienture's mission to provide innovative treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose. As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and advocacy groups to enhance awareness, education, and distribution efforts.
Nasal delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market.

Government

Regulations

Scienture Partners with Kindeva to Launch 10mg REZENOPY Nasal Spray for Opioid Overdose Treatment, Secures Exclusive US Rights to FDA-Approved Spray

GBTG

Amex GBT Receives Approval From UK Competition And Markets Authority To Complete Its Acquisition Of CWT

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $200 price target.

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $200 Price Target

Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).
The SKNJCT-003 clinical study is currently underway in nine (9) clinical sites in United States and is expected to randomize 60 patients. The interim analysis was conducted after more than 50% of the targeted 60 patients in the study were randomized.
The interim analysis shows the clinical study SKNJCT-003 is trending positively with a proportion of subjects with complete clinical clearance of more than 60%. The analysis also shows the investigational product, D-MNA was well tolerated for both dose levels, a low-dose group receiving 100ug of D-MNA and a high-dose group receiving 200ug of D-MNA in all participants so far enrolled in the study, with no dose limiting toxicities (DLTs), or serious adverse events (SAEs). In addition, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examination. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.
The Company plans to submit the interim analysis to the United States Food and Drug Administration (FDA) as part of a package seeking a Type C meeting with the FDA in Q2 2025. The purpose of the Type C meeting is to formally discuss the product development and gain further alignment on the clinical pathway. The Company's aim is to gain FDA's consent to fast-track the clinical development program.
"We are immensely encouraged by the positively trending interim analysis", stated Dr. Raza Bokhari, Executive Chairman &amp; CEO. "The interim analysis brings us one step closer to delivering a novel, non-invasive treatment for BCC".
Clinical Trial Design&nbsp;
The clinical study is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 60 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.
The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021. SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.
The Company also has submitted a clinical design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH). The study is expected to randomize 36 patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi&nbsp;(CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).

MDCX

Medicus Pharma Reports Interim Results in Phase 2 Trial for Non-Invasive Skin Cancer Treatment,  Seeks FDA Meeting After Promising 60% Clearance Rate in Basal Cell Carcinoma Study

Comments

Global X Cybersecurity ETF

Noticias

Últimas noticias sobre Global X Cybersecurity ETF (NASDAQ:BUG)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL